首页» 中心PI» 曹云龙
联系方式

E-mail:yunlongcao@pku.edu.cn
办公地点:综合科研2号楼102室

研究组主页:

曹云龙
BIOPIC研究员
个人履历

2023.03-至今 北京大学生物医学前沿创新中心(BIOPIC),tenure-track助理教授、研究员
2022.03-2023.03 北京大学生物医学前沿创新中心(BIOPIC),副研究员
2019.09-2022.03 北京大学生物医学前沿创新中心(BIOPIC),助理研究员
2014-2019 哈佛大学,化学与化学生物学系,化学(博士) 导师:谢晓亮
2010-2014 浙江大学,竺可桢学院,物理(学士)

主要研究方向

B细胞介导的体液免疫是人体抵御外来病原的重要机制。深入理解适应性体液免疫应答是开发传染病广谱抗体药物和高效广谱疫苗的关键。本实验室主要聚焦B细胞适应性免疫应答与抗体抗原相互作用,开展以下科学问题的研究与探索:1)基于中和抗体高通量表征的新冠病毒免疫逃逸突变预测;2)针对呼吸道传染性病毒(如新冠、流感等)广谱黏膜疫苗设计与广谱抗体药物研制;3)体液免疫印迹、免疫衰减和免疫记忆的分子机制研究;4)基于高通量实验数据与机器学习模型的抗原表位特异性抗体人工设计。

获奖及荣誉
2023.02 2022年度中国十大医学科技新闻
2023.01 2022年度中国生命科学十大进展
2022.12 2022年度 Nature 十大人物
2022.08 国家自然科学基金委优秀青年科学基金
2022.08 2021年度北京市科技进步一等奖(排名第 7)
2022.01 《麻省理工科技评论》2021 年度中国“35 岁以下科技创新 35 人”(TR35)
代表性论文及论著
  1. Y. Cao*#, F. Jian#, J. Wang#, Y. Yu#, W. Song#, A. Yisimayi, J. Wang, R. An, X.Chen, N. Zhang, Y. Wang, P. Wang,L. Zhao, H. Sun, L. Yu, S. Yang, X. Niu, T. Xiao, Q. Gu, F. Shao, X. Xiao, Y. Xu, R. Jin, Z. Shen, Y. Wang* & X.S. Xie*, Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. (2022). 
  2. Y. Cao*#, A. Yisimayi#, F. Jian#, W. Song#, T. Xiao#, L. Wang#, S. Du#, J. Wang#, Q. Li#, X. Chen#, Y. Yu#, P. Wang,Z. Zhang, P. Liu, R. An, X. Hao, Y. Wang, J. Wang, R. Feng, H. Sun, L. Zhao, W. Zhang, D. Zhao, J. Zheng, L. Y,C. Li, N. Zhang, R. Wang, X. Niu, S. Yang, X. Song, Y. Chai, Y. Hu, Y. Shi, L. Zheng, Z. Li, Q. Gu, F. Shao, W.Huang, R. Jin, Z. Shen*, Y. Wang*, X. Wang*, J. Xiao* & X. S. Xie*, BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 608: 593-602. (2022). 
  3. Y. Cao*#, J. Wang#, F. Jian#, T. Xiao#, W. Song#, A. Yisimayi#, W. Huang#, Q. Li, P. Wang, R. An, J. Wang, Y. Wang, X. Niu, S. Yang, H. Liang, H. Sun, T. Li, Y. Yu, Q. Cui, S. Liu, X. Yang, S. Du, Z. Zhang, X. Hao, F. Shao,R. Jin, X. Wang*, J. Xiao*, Y. Wang* & X. S. Xie*, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 602: 657-663. (2022). 
  4. Z. Cui#, P. Liu#, N. Wang#, L. Wang#, K. Fan#, Q. Zhu#, K. Wang#, R. Chen, R. Feng, Z. Jia, M. Yang, G. Xu, B. Zhu, W. Fu, T. Chu, L. Feng, Y. Wang, X. Pei, P. Yang, X. S. Xie, L. Cao*, Y. Cao*, X. Wang*, Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 185(5): 860-871. (2022). 
  5. S. Du#, Y. Cao#, Q. Zhu#, P. Yu#, F. Qi#, G. Wang, X. Du, L. Bao, W. Deng, H. Zhu, J. Liu, J. Nie, Y. Zheng, H. Liang, R. Liu, S. Gong, H. Xu, A. Yisimayi, Q. Lv, B. Wang, R. He, Y. Han, W. Zhao, Y. Bai, Y. Qu, X. Gao, C. Ji,Q. Wang, N. Gao, W. Huang, Y. Wang, X. S. Xie*, X. Su*, J. Xiao*, C. Qin*, Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.Cell. 183: 1013-1023.e13 (2020). 
  6. Y. Cao#, B. Su#, X. Guo#, W. Sun#, Y. Deng#, L. Bao#, Q. Zhu, X. Zhang, Y. Zheng, C. Geng, X. Chai, R. He, X. Li,Q. Lv, H. Zhu, W. Deng, Y. Xu, Y. Wang, L. Qiao, Y. Tan, L. Song, G. Wang, X. Du, N. Gao, J. Liu, J. Xiao, X. Su,Z. Du, Y. Feng, C. Qin*, C. Qin*, R. Jin*, X. S. Xie*, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 182: 73-84.e16 (2020). 
  7. C. Yue, W. Song, L. Wang, F. Jian, X. Chen, F. Gao, Z. Shen, Y. Wang, X. Wang*, Y. Cao*, ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. The Lancet Infectious Diseases (2022). https://doi.org/10.1016/S1473-3099(23)00010-5
  8. Y. Cao*#, F. Jian#, Z. Zhang#, A. Yisimayi#, X. Hao#, L. Bao#, F. Yuan, Y. Yu, S. Du. J. Wang, T. Xiao, W. Song, Y. Zhang, P. Liu, R. An, P. Wang, Y. Wang, S. Yang, X. Niu, Y. Zhang, Q. Gu, F. Shao, Y. Hu, W. Yin, A. Zheng, Y. Wang, C. Qin*, R. Jin*, X. Xiao* & X. S. Xie*, Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Reports. 41(12): 111845 (2022).
  9. Y. Cao*#, W. Song#, L. Wang#, P. Liu#, C. Yue#, F. Jian#, Y. Yu, A. Yisimayi, P. Wang, Y. Wang, Q. Zhu, J. Deng, W. Fu, L. Yu, N. Zhang, J. Wang, T. Xiao, R. An, J. Wang, L. Liu, S. Yang, X. Niu, Q. Gu, F. Shao, X. Xiao, B. Meng,R. K. Gupta, R. Jin, Y. Wang, X. S. Xie* & X. Wang*, Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host & Microbe. 30(11): 1527-1539. (2022).
  10. F. Jian#, Y. Yu#, W. Song, A. Yisimayi, L. Yu, Y. Gao, N. Zhang, Y. Wang, F. Shao, X. Xiao, Y. Xu, R. Jin, Y. Wang,X. S. Xie* & Y. Cao*, Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.The Lancet Infectious Diseases. 22(11): 1535-1537. (2022).
  11. H. Zheng#, Y. Cao*#, X. Chen#, F. Wang, Y. Hu, W. Song, Y. Chai, Q. Gu, Y. Shi, Y. Feng, S. Liu, Y. Xie, X. S. Xie,W. Jiang, Z. Shen*, Disease profile and plasma neutralizing activity of post-vaccination Omicron BA.1 infection in Tianjin, China: a retrospective study. Cell Research. 32: 781-784. (2022).
  12. Y. Cao*#, X. Hao#, X. Wang#, Q. Wu#, R. Song, D. Zhao, W. Song, Y. Wang, A. Yisimayi, W. Wang, W. Zhang, J. Du, H. Yu*, X. S. Xie*, R. Jin*, Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Research. 32: 107-109. (2022).
  13. S. Du#, P. Liu#, Z. Zhang#, T. Xiao, A. Yasimayi, W. Huang, Y. Wang, Y. Cao*, X. S. Xie*, J. Xiao*, Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants. Cell Research. 31: 1130-1133. (2021).
  14. Y. Cao*#, A. Yisimayi#, Y. Bai#, W. Huang#, X. Li#, S. Du#, T. Yuan#, R. An, J. Wang, T. Xiao, W. Ma, L. Song, Y. Li, X. Li, W. Song, J. Wu, S. Liu, X. Li, Y. Zhang, B. Su, X. Guo, Z. Zhang, Y. Wei, C. Gao, Y. Dou, X. Xu, N. Zhang, Y. Zhang, R. Shi, R. Jin, Y. Ma, B. Lu, Y. Feng*, C. Qin*, Y. Wang*, J. Xiao*, X. S. Xie*, Humoral immune response to circulating SARS-CoV-2 variants by inactivated and RBD-subunit vaccines. Cell Research. 31: 732–741. (2021).